Twist Bioscience Corporation: research and development expense
Research and development expense for Twist Bioscience Corporation. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Twist Bioscience Corporation financial histories
What this measure means
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
Exact concept: us-gaap:ResearchAndDevelopmentExpense. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2016-10-01 to 2025-09-30. The SEC response was captured on 2026-09-19.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2024-10-01 | 2025-09-30 | 80,285,000 | USD | 2025-11-17 | 10-K · 0001581280-25-000025 |
| 2023-10-01 | 2024-09-30 | 90,852,000 | USD | 2025-11-17 | 10-K · 0001581280-25-000025 |
| 2022-10-01 | 2023-09-30 | 106,894,000 | USD | 2025-11-17 | 10-K · 0001581280-25-000025 |
| 2021-10-01 | 2022-09-30 | 120,307,000 | USD | 2024-11-18 | 10-K · 0001628280-24-048262 |
| 2020-10-01 | 2021-09-30 | 69,072,000 | USD | 2023-11-21 | 10-K · 0001628280-23-039767 |
| 2019-10-01 | 2020-09-30 | 43,006,000 | USD | 2023-06-05 | 10-K/A · 0001628280-23-020881 |
| 2018-10-01 | 2019-09-30 | 35,683,000 | USD | 2021-11-23 | 10-K · 0001104659-21-142700 |
| 2017-10-01 | 2018-09-30 | 20,347,000 | USD | 2020-11-27 | 10-K · 0001193125-20-303904 |
| 2016-10-01 | 2017-09-30 | 19,169,000 | USD | 2019-12-13 | 10-K · 0001193125-19-313115 |
Related financial histories
- Twist Bioscience Corporation: total assets
- Twist Bioscience Corporation: total liabilities
- Twist Bioscience Corporation: stockholders equity
- Twist Bioscience Corporation: cash and cash equivalents
- Twist Bioscience Corporation: net income or loss
- Twist Bioscience Corporation: operating cash flow
- Twist Bioscience Corporation: capital expenditure payments
- Twist Bioscience Corporation: financing cash flow
- Twist Bioscience Corporation: investing cash flow
- Twist Bioscience Corporation: retained earnings or deficit
- Twist Bioscience Corporation: basic weighted-average shares
- Twist Bioscience Corporation: diluted weighted-average shares
- Twist Bioscience Corporation: basic earnings per share
- Twist Bioscience Corporation: diluted earnings per share
- Twist Bioscience Corporation: income tax expense or benefit
- Twist Bioscience Corporation: net property, plant and equipment
- Twist Bioscience Corporation: share-based compensation expense
- Twist Bioscience Corporation: operating income or loss
- Twist Bioscience Corporation: current assets
- Twist Bioscience Corporation: interest expense
- Twist Bioscience Corporation: current liabilities
- Twist Bioscience Corporation: current accounts payable
- Twist Bioscience Corporation: goodwill carrying amount
- Twist Bioscience Corporation: net finite-lived intangible assets
- Twist Bioscience Corporation: net current accounts receivable
- Twist Bioscience Corporation: net inventory
- Twist Bioscience Corporation: cost of revenue
- Twist Bioscience Corporation: selling, general and administrative expense
Inspect the source
- Entity
- Twist Bioscience Corporation / CIK 0001581280
- Captured
- 2026-09-19T11:19:15.190Z
- SEC response SHA-256
ab4d6e344a91d7c2894dc8c0601b52f05230299434ff75bf5209b39897d81702
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001581280.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))